These three tools get compared constantly, and the comparison is usually framed as "which is best". That is the wrong question, because they occupy different layers of the same stack. The right question is which layer you are actually missing.
Answer that first and the choice becomes obvious. Get it wrong and you will spend a year with an expensive tool that solves a problem you did not have.
Lusha — the data layer
Lusha finds people. Verified work emails, direct-dial phone numbers, company firmographics and buying signals, delivered through a Chrome extension, a prospecting workspace, a REST API and an MCP server. It scores 8.1/10 on our scale, with 8.9 for ease of use.
What it deliberately does not do is manage the conversation afterwards. There is no sequencer, no dialer, no meeting scheduler, no pipeline. Lusha assumes you already own those things and just need better inputs going into them.
That assumption is the whole buying decision. If you have a working CRM and a sequencing tool and your problem is that the contact data going into them is thin or wrong, Lusha is precisely the right purchase — a free plan, published pricing on every self-serve tier, and the strongest compliance record in the category.
Amplemarket — the platform layer
Amplemarket bundles prospecting, multi-channel sequences and lead generation into one AI-driven platform. It scores 6.4/10 with us, and pricing is enterprise-only — there is no published self-serve tier and no free plan.
The bundle is the point and also the risk. One vendor for data and outreach means one integration, one invoice, one place to look when something breaks. It also means the quality of your contact data and the quality of your sequencing engine are now the same procurement decision, and you cannot swap one without swapping both.
Amplemarket makes most sense for a team that is building an outbound motion from nothing and wants a single opinionated system. It makes least sense for a team that already likes its sequencer.
Close — the relationship layer
Close is a CRM with calling, email and SMS built directly into it, scoring 7.5/10. Pricing starts at $49/month for Startup and $299/month for Professional. Its whole design goal is removing the app-switching that kills a small sales team's call volume.
Close does not find you contacts. It is where contacts live once found, and it is very good at making sure a rep can dial without leaving the record. If your problem is that reps spend the morning copying numbers between four tabs, Close fixes that and Lusha does not.
The natural pairing is obvious once you see the layers: Lusha finds the number, Close dials it and remembers what happened. They are complements, not competitors, and plenty of teams run both.
The decision, in three questions
Rather than comparing feature grids, answer these in order. The first "no" is your answer.
- Do you have a system of record where every deal lives? If no, buy Close or HubSpot's free CRM first. Contact data poured into no system is contact data lost.
- Do you have a way to sequence and dial at volume? If no, buy Close, or Amplemarket if you want data and outreach from one vendor.
- Do you have both, and the problem is that the contacts are wrong, missing phone numbers, or six months stale? That is exactly the Lusha problem, and it is the one Lusha is best in class at.
Cost over a year, honestly
Lusha Pro at the annual rate is about $629 a year for two seats and 7,200 credits. Close Startup is $588 a year per seat before you add users. Amplemarket requires a sales conversation and an annual commitment, so budget for enterprise pricing rather than the others' self-serve range.
Two seats on Lusha plus two on Close lands around $1,800 a year and covers the data layer and the relationship layer properly. That is the configuration we would recommend to most sub-ten-person outbound teams — and it is cheaper than most single enterprise platform contracts.
One caveat that applies to all three: Lusha and Amplemarket both sell on annual commitments that are difficult to downgrade mid-term. Get the exit terms in writing before signing either.